GSK Spin-Out NeRRe Raises £23m For NK Antagonists
Executive Summary
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
You may also be interested in...
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.
Ogeda Seeks Financing After Successful Phase II For Non-Hormonal Menopause Drug
Ogeda's non-hormonal menopause therapy, fezolinetant, has produced positive results in Phase II – an important step for the small Belgian biotech as it looks for partners or investment from further afield.